Unknown

Dataset Information

0

Nano vaccines for T. gondii Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis.


ABSTRACT: Caused by Toxoplasma gondii, toxoplasmosis has aroused great threats to public health around the world. So far, no effective vaccine or drug is commercially available, and the demands for a safe and effective therapeutic strategy have become more and more urgent. In the current study, we constructed a DNA vaccine encoding T. gondii ribosomal P2 protein (TgP2) and denoted as TgP2-pVAX1 plasmid. To improve the immunoprotection, nanomaterial poly-lactic-co-glycolic acid (PLGA) and chitosan were used as the delivery vehicle to construct TgP2-pVAX1/PLGA and TgP2-pVAX1/CS nanospheres. Before vaccinations in BALB/c mice, TgP2-pVAX1 plasmids were transiently transfected into Human Embryonic Kidney (HEK) 293-T cells, and the expression of the eukaryotic plasmids was detected by laser confocal microscopy and Western blotting. Then the immunoprotection of naked DNA plasmids and their two nano-encapsulations were evaluated in the laboratory animal model. According to the investigations of antibody, cytokine, dendritic cell (DC) maturation, molecule expression, splenocyte proliferation, and T lymphocyte proportion, TgP2-pVAX1 plasmid delivered by two types of nanospheres could elicit a mixed Th1/Th2 immune response and Th1 immunity as the dominant. In addition, TgP2-pVAX1/PLGA and TgP2-pVAX1/CS nanospheres have great advantages in enhancing immunity against a lethal dose of T. gondii RH strain challenge. All these results suggested that TgP2-pVAX1 plasmids delivered by PLGA or chitosan nanomaterial could be promising vaccines in resisting toxoplasmosis and deserve further investigations and applications.

SUBMITTER: Yu Z 

PROVIDER: S-EPMC8899214 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nano vaccines for <i>T. gondii</i> Ribosomal P2 Protein With Nanomaterials as a Promising DNA Vaccine Against Toxoplasmosis.

Yu ZhengQing Z   He Ke K   Cao WanDi W   Aleem Muhammad Tahir MT   Yan RuoFeng R   Xu LiXin L   Song XiaoKai X   Li XiangRui X  

Frontiers in immunology 20220221


Caused by <i>Toxoplasma gondii</i>, toxoplasmosis has aroused great threats to public health around the world. So far, no effective vaccine or drug is commercially available, and the demands for a safe and effective therapeutic strategy have become more and more urgent. In the current study, we constructed a DNA vaccine encoding <i>T. gondii</i> ribosomal P2 protein (TgP2) and denoted as TgP2-pVAX1 plasmid. To improve the immunoprotection, nanomaterial poly-lactic-<i>co</i>-glycolic acid (PLGA)  ...[more]

Similar Datasets

| S-EPMC7533317 | biostudies-literature
| S-EPMC8068005 | biostudies-literature
| S-EPMC5678475 | biostudies-literature
| S-EPMC3744524 | biostudies-literature
| S-EPMC3691725 | biostudies-literature
| S-EPMC8205521 | biostudies-literature
| S-EPMC10070739 | biostudies-literature
| S-EPMC2717496 | biostudies-literature
| S-EPMC8890382 | biostudies-literature
| S-EPMC9785012 | biostudies-literature